FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
What's Your Reaction?
